

Regenexx® at Work
NOVEMBER 2026 | VOLUME 47

KEY TAKEAWAYS

- **Targeted Dosing and Precision:** Guided injections with optimized cell concentrations deliver longer-lasting results.
- **Data Backed Claims:** Long-term results tracking supports treatment outcomes and MSK savings.
- **Fewer Surgeries, Greater Savings:** Helping employees avoid costly operations supports human capital and health plan savings.
- **Validation in Action:** Frank Roby, CEO, Averify, shares their audit results.

3-MINUTE READ

Dose, Data, and Durability: Rethinking Non-Surgical Orthopedic Care

For self-funded employers, musculoskeletal (MSK) care is one of the largest and most unpredictable healthcare costs. While many digital MSK programs and pharmaceuticals promise quick fixes, **real value requires precise care, tracked results, and data-backed outcomes**. Benefits leaders should look at three core pillars when weighing the value of adding an orthobiologic MSK solution: **Dose, Data, and Durability**.[1]

Dose: Getting the Precision Right

Effective orthobiologic care requires delivering optimal cell concentrations, such as Bone Marrow Concentrate (BMC)† and Platelet-Rich Plasma (PRP), directly to the injured site.[2–4]

- **Optimized Dosing:** Advanced processing produces cell concentrations matched to specific joint conditions.[2–4]
- **Targeted Guidance:** Precision imaging (ultrasound or fluoroscopy) ensures accurate cell placement.[2–4]
- **Proven Outcomes:** Clinical research links cell optimization and injection precision to durable, long-term results.[2–4]

Regenexx accounts for roughly half of all global research on bone marrow concentrate in orthopedics. Its proprietary protocols align directly with the five core criteria insurers require for clinical evaluation.[5]


Data: Proving Outcomes Over Time

Sustained value requires hard data demonstrating both long-term clinical success and health plan cost savings.[1,6,7]

- **20+ Years of Data:** Ongoing tracking validates long-term procedure results and surgical avoidance.[6]
- **Validated Audits:** Independent evaluations confirm plan savings that match predicted cost reductions.[1,7]
- **Network Accountability:** Real-world tracking holds every clinical provider to consistent quality standards.[1,6]

The active Regenexx registry tracks tens of thousands of network procedures long-term. As one example, as of November 2, 2026, data across 27,840 knee procedures shows an average 39% functional improvement just one month post-procedure.[6]

Overall Knee Improvement After Procedure Using Regenexx Injectates



Patients feel their joints are, on average, already 39% better after only 1-month, and continue to improve from there. The questionnaire used is the Single Assessment Numeric Evaluation (SANE).

Data updated November 2, 2026.

Durability: Multifaceted, Multi-Year Savings

Employer MSK programs should help staff avoid costly operations, protecting human capital while driving multi-year plan savings.[1,8,9]

- **Long-Lasting Results:** Optimized dose procedures performed with image guidance support multi-year impacts, reducing repeat care and surgical spend.[1,6,8,9]
- **Surgical Avoidance:** Comparative studies show significant spending drops by safely diverting patients from major surgeries.[8,9‡]
- **High-Impact ROI:** Replacing elective orthopedic surgeries with non-surgical orthobiologics delivers immediate and predictable savings based on mmber populations.[1,7–9]

Longitudinal commercial claims research confirms that orthobiologic care through the Regenexx benefit averts surgery rather than merely delaying it, keeping downstream medical utilization consistently low.[8,9‡]



REGENEXX CORPORATE PROGRAM: VALIDATION IN ACTION

Q: Many vendors self-report their savings. How did your independent third-party audit compare to what was reported?

What was interesting in the case of Regenexx, which is not always the case—in fact, many times is not the case—our number for validating the performance they delivered, the actual savings and the value to the plan, was almost identical to their number, which meant that they did it right... our independent third-party review confirmed that in fact they were there. We rated their savings at 64% off of the normative charge. They weighted themselves at 66%. So, 2% is pretty close.

— Frank Roby, CEO, Averify

Watch the full video at regenexxcorporate.com/dose-data-and-durability/

Why partner with the Regenexx Corporate Program?

Traditional health insurance rarely covers advanced regenerative orthopedics. The Regenexx Corporate Program bridges this gap by providing self-funded employers, brokers, and third-party administrators (TPAs) with a turnkey, $0-cost implementation benefit that offers employees and their dependents direct access to a proven, non-surgical alternative for orthopedic pain and musculoskeletal (MSK) injuries.

Key Program and Benefit Value Drivers:

Managing musculoskeletal spend requires controlling both upfront procedure costs and long-term care utilization. The Regenexx Corporate Program delivers an evidence-based pathway that addresses both:

Validated Initial Savings: An independent cost-savings analysis by the Validation Institute confirms that procedures using Regenexx injectates average ~50% savings compared to the surgery avoided.[7] Many program partners report reducing their costs by up to 70% on individual surgical procedures.[6]

Proven Long-Term Cost Control: Real-world commercial claims studies by Duke University researchers show Regenexx orthobiologic procedures consistently drive lower total 12- and 24-month healthcare spending compared to surgical alternatives like knee replacements, meniscectomies, and lumbar fusions.[8,9]

True Surgery Avoidance: Duke University research confirmed that orthobiologics avert surgery instead of merely delaying it, maintaining low reoperation rates and significantly lower downstream medical utilization over multi-year follow-ups.[8,9]

Contact your Regenexx Corporate Sales Representative to learn more.

6151 Thornton Avenue, Suite 400
Des Moines, IA 50321
regenexxcorporate.com

877.341.5968

Regenexx® Corporate Program

Terminology Notes & Footnotes

*Orthobiologics: Naturally derived substances that, when administered into bones, joints, muscles, ligaments, or tendons, can support the body's natural healing processes. The "biologics" suffix in the term "orthobiologics" is not to be confused with the way the standalone "biologics" term is used in pharmaceuticals (particularly rheumatology). In pharmaceuticals, "biologics" often refers to prescription drugs that are made by living organisms (recombinant DNA technology) or contain a component of a living organism.

†Bone Marrow Concentrate (BMC): BMC contains stem cells and native growth factors. Patients often characterize Regenexx's non-surgical treatment options as "stem cell" or "regenerative medicine" procedures using Regenexx lab processes. For more information about these terms and how Regenexx defines them, please visit Regenexx Our Approach https://regenexx.com/our-approach/stem-cells/

‡Duke Study Disclaimer: The Duke study data have not yet been finalized by authors. This information may contain errors and report information that is not yet accepted or endorsed by the scientific or medical community. The Duke knee and spine studies were sponsored by Regenexx. Per the knee and spine study papers, the sponsor had no role in the conduct of the analyses, interpretation of the data, or manuscript preparation. Duke University investigators had full access to all study data and retained final responsibility for the content of the manuscripts and the decision to submit for publication. Both studies were retrospective, observational analyses using propensity-matched cohorts representing patients who elected orthobiologic treatment among those eligible for surgery; as with any non-randomized comparison, the potential for selection bias cannot be fully excluded.

References & Video Citations

1. Regenexx Corporate & Video Reference: Roby, Frank CEO, Averify). Video Interview on Healthcare Cost Savings and Surgical Avoidance. Published October 16, 2026. Featured on Regenexx Corporate Dose, Data, and Durability.

2. Centeno C. PRP concentration vs. dose: why concentration is as important as dose. Regenexx Blog. Published March 10, 2024. Accessed September 11, 2026. https://regenexx.com/blog/prp-concentration-vs-dose-why-concentration-is-where-we-need-to-focus/

3. Centeno C. Bone marrow stem cell dose matters in knee osteoarthritis. Regenexx Blog. Published August 10, 2022. Accessed September 11, 2026. https://regenexx.com/blog/bone-marrow-stem-cell-dose-matters-in-knee-osteoarthritis/

4. Centeno C. Another new study says PRP dose is critical: why we have ALWAYS used high dose PRP. Regenexx Blog. Published March 26, 2024. Accessed September 11, 2026. https://regenexx.com/blog/new-study-says-prp-dose-is-critical-why-we-have-always-used-high-dose-prp/

5. Regenexx Corporate. Advanced Non-Surgical Orthopedic Procedures & Treatments. Accessed November 10, 2026. https://regenexxcorporate.com/orthopedic-procedures/

6. Regenexx Patient Registry: Internal Registry Data on File (2005–Present).

7. Validation Institute. Validation Report: Regenexx Corporate Program. Published 2023. Accessed May 14, 2024.

8. Lentz TA, Burrows J, Brucker A, et al. Comparative Analysis of Health Care Use and Costs for Orthobiologic versus Surgical Treatments in Economically High-Impact Knee Conditions. medRxiv. Preprint published February 27, 2026. doi:10.64898/2026.02.27.26347270

9. Lentz TA, Burrows J, Brucker A, et al. Spine-Related Health Care Utilization and Costs Following Orthobiologic Injection Versus Lumbar Surgery for Degenerative Spine Conditions. medRxiv. Preprint published March 31, 2026. doi:10.64898/2026.03.31.26349877

Medical & Regulatory Disclaimers

Like all medical interventions, procedures using Regenexx lab processes have a success and failure rate. Regenexx provider patient reviews and testimonials in this email should not be interpreted as a statement on the effectiveness of regenerative therapy for anyone else. Industry professional reviews and testimonials reflect the experience of that entity with the Regenexx Corporate Program. To discuss what a partnership with Regenexx could look like for your company or client, contact our team.

The information provided by Regenexx is for informational purposes only and is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. Regenexx is not a teaching institution or medical practice, and does not engage in the training of physicians or the practice of medicine. Physicians listed on the Regenexx websites are independent contractors who have licensed certain Regenexx intellectual property. Nothing on the Regenexx webpages, the Regenexx blog, any informational videos, or other marketing materials should be interpreted as endorsing a particular physician or establishing an employer-employee, partnership, or agency relationship between Regenexx and any physician.

Regenexx will never sell your information and is committed to your privacy.

No longer interested in receiving the Regenexx at Work Newsletter? Reply to this email and let us know.

© Regenexx Corporate 2026. All rights reserved.

Regenexx® Corporate Program

6151 Thornton Avenue, Suite 400
Des Moines, IA 50321
regenexxcorporate.com
877.341.5968